Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belcesiran Open-Label Extension in PiZZ AATLD
NCT05146882Phase 2Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Primary completion
- May 2022
- Modality
- Gene Editing, Antisense DNA, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of belcesiran in alpha-1 antitrypsin deficiency (AATD) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Incidence of treatment-emergent adverse events up to 152 weeks, Change from baseline in pulmonary function tests (PFTs) up to 152 weeks and 4 more. Planned start Dec 2021; status: withdrawn.
02
Drugs
belcesiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT05146882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05146882.